t(3;17)(q26;q22)

Clinics and Pathology

Disease	Chronic myelogenous leukaemia with t(9;22)(q34;q11) and blast crisis of CML (BC-CML) (4 cases altogether), other myeloproliferative syndromes, Acute myeloid leukaemia (AML)
Epidemiology	At least 9 cases to date, aged 62 years (medain, range: 49-78); sex ration was 5M/3F.
Prognosis	No data

Cytogenetics

Cytogenetics Morphological

Sole anomaly in 3 cases, with t(9;22)(q34;q11) in 4 cases (one of which was a complex translocation), with del(5q) (1 case), and with del(7q), and +21 in 1 case.

Genes involved and Proteins

Note	The partner of EVI1 is yet unknown.

Gene Name	EVI1
Location	3q26.2
Protein	Transcrition factor; EVI1 targets include:GATA2, ZBTB16 /PLZF, ZFPM2/FOG2, JNK and the PI3K/AKT pathway. Role in cell cycle progression, likely to be cell-type dependant; antiapoptotic factor; involved in neuronal development organogenesis; role in hematopoietic differsntiation

External links

Other database	t(3;17)(q26;q22)	Mitelman database (CGAP - NCBI)
Other database	t(3;17)(q26;q22)	CancerChromosomes (NCBI)

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity: you are welcome to submit a paper to our new Case Report section.

Bibliography

Translocation t(3;17)(q26;q22): a marker of acute disease in myeloproliferative disorders?

Mecucci C, Michaux JL, Broeckaert-Van Orshoven A, Symann M, Boogaerts M, Kulling G, Van den Berghe H

Cancer genetics and cytogenetics. 1984 ; 12 (2) : 111-119.

PMID 6722753

New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in acceleration.

Mugneret F, Solary E, Favre B, Caillot D, Sidaner I, Guy H

Cancer genetics and cytogenetics. 1992 ; 60 (1) : 90-92.

PMID 1591713

Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.

Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P

Blood. 1995 ; 86 (9) : 3542-3552.

PMID 7579462

Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features.

Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, Thomas X

The hematology journal : the official journal of the European Haematology Association / EHA. 2002 ; 3 (1) : 21-31.

PMID 11960392

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Lˆwenberg B, Delwel R

Blood. 2003 ; 101 (3) : 837-845.

PMID 12393383

EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.

Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, De Paepe A, Cervera J, Recher C, De Mas V, Hagemeijer A, Speleman F

Genes, chromosomes & cancer. 2006 ; 45 (4) : 349-356.

PMID 16342172

The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.

Wieser R

Gene. 2007 ; 396 (2) : 346-357.

PMID 17507183

Contributor(s)

Written	07-2007	Jean-Loup Huret
		Jean Loup HURET, Genetics, Dept Medical Information, University of Poitiers; CHU Poitiers Hospital, F-86021 Poitiers, France

Citation

This paper should be referenced as such :

Huret JL . t(3;17)(q26;q22). Atlas Genet Cytogenet Oncol Haematol. July 2007 . URL : http://AtlasGeneticsOncology.org/Genes/t0317q26q22ID1282.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Mon Jul 14 16:32:57 2008

For comments and suggestions or contributions, please contact us